Adverum Biotechnologies (DB:AVU0) - Cotización, noticias y análisis

Resumen de acción AVU0

Adverum Biotechnologies, Inc. es una empresa en fase clínica que desarrolla candidatos a productos de terapia génica para tratar enfermedades oculares.

Acerca de la empresa

AVU0 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 44.59%

Análisis de riesgos

Alta volatilidad del precio de la acción en los últimos 3 meses

Se prevé que los beneficios disminuyan un promedio de 9.5% al año durante los próximos 3 años

Los accionistas han sido diluidos sustancialmente en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

+ 1 riesgos adicionales

Competidores de Adverum Biotechnologies, Inc.

Heidelberg Pharma

XTRA:HPHA

€138.9m

4SC

DB:VSC

€79.9m

Medigene

XTRA:MDG1

€37.9m

Formycon

XTRA:FYB

€762.9m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Adverum Biotechnologies
Historical stock prices
Current Share Price	US$14.80
52 Week High	US$27.80
52 Week Low	US$6.60
Beta	0.79
1 Month Change	0%
3 Month Change	38.32%
1 Year Change	112.95%
3 Year Change	-52.26%
5 Year Change	-74.71%
Change since IPO	-91.95%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	AVU0	DE Biotechs	Mercado DE
7D	0%	2.1%	-1.0%
1Y	112.9%	-22.4%	2.0%

Rentabilidad vs. Industria: AVU0 superó al sector German Biotechs , que obtuvo un rendimiento del -24.4% el año pasado.

Rentabilidad vs. Mercado: AVU0 superó al mercado German, que obtuvo un rendimiento del 2.3% el año pasado.

Volatilidad de los precios

Is AVU0's price volatile compared to industry and market?
AVU0 volatility
AVU0 Average Weekly Movement	32.0%
Biotechs Industry Average Movement	5.1%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: El precio de las acciones de AVU0 ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de AVU0 ha aumentado de 17% a 30% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2006	121	Laurent Fischer	adverum.com

Adverum Biotechnologies, Inc. es una empresa en fase clínica que desarrolla productos de terapia génica candidatos para el tratamiento de enfermedades oculares. Su principal producto candidato es el ixoberogene soroparvovec (ADVM-022), un candidato a terapia génica de inyección intravítrea única utilizado para el tratamiento de pacientes con degeneración macular húmeda asociada a la edad y edema macular diabético, que se encuentra en ensayos clínicos de fase 2. La empresa está desarrollando ADVM-062 (AAV.7m8-L-opsina), un nuevo producto de terapia génica candidato para el tratamiento de la monocromía de conos azules mediante una única inyección intravítrea.

Resumen de fundamentos de Adverum Biotechnologies, Inc.

¿Cómo se comparan los beneficios e ingresos de Adverum Biotechnologies con su capitalización de mercado?
Estadísticas fundamentales de AVU0
Capitalización bursátil	€192.65m
Beneficios(TTM)	-€108.75m
Ingresos (TTM)	€3.34m

57.7x

Ratio precio-ventas (PS)

-1.8x

Ratio precio-beneficio (PE)

¿Está AVU0 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de AVU0
Ingresos	US$3.60m
Coste de los ingresos	US$77.68m
Beneficio bruto	-US$74.08m
Otros gastos	US$43.09m
Beneficios	-US$117.16m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-5.65
Margen bruto	-2,057.67%
Margen de beneficio neto	-3,254.58%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado AVU0 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción AVU0

Recompensas

Análisis de riesgos

Competidores de Adverum Biotechnologies, Inc.

XTRA:HPHA

€138.9m

DB:VSC

€79.9m

XTRA:MDG1

€37.9m

XTRA:FYB

€762.9m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD

Adverum Biotechnologies, Inc. Announces Stipulation and Agreement of Settlement

Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Recent updates

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD

Adverum Biotechnologies, Inc. Announces Stipulation and Agreement of Settlement

Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors

Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD

Adverum Biotechnologies Receives Nasdaq Notice on Regained Compliance with Minimum Bid Price Requirement

Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer

Adverum Biotechnologies, Inc. Receives Approval from the Listing Qualifications Department of Nasdaq to Transfer the Listing of Common Stock from Nasdaq Global Market to Nasdaq Capital Market

Adverum Biotechnologies, Inc. Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

Adverum Biotechnologies, Inc. Appoints Linda Rubinstein as Chief Financial Officer

Adverum Biotechnologies, Inc. Announces New Data from the OPTIC Study Treating Wet Age-Related Macular Degeneration

Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration

Adverum Biotechnologies, Inc. Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After A Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD

Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

Adverum Biotechnologies, Inc. Completes IND Amendment and Prepares to Initiate Phase 2 LUNA Trial of ADVM-022 in Wet AMD

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 2000 Dynamic Index

Adverum Biotechnologies, Inc. Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After A Single IVT Injection of ADVM-022 in the Optic Study in Wet AMD

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies Announces New Data At the Macula Society's 2022 Annual Meeting

Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of Its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy

Adverum Biotechnologies, Inc. Presents Data At American Society of Gene and Cell Therapy Further Supporting Phase 2 Development Plans for ADVM-022

Adverum Biotechnologies, Inc. Presents Additional Efficacy and Safety Data from the Optic Trial of ADVM-022 in Wet AMD At the ARVO 2022 Annual Meeting

High number of new directors

Adverum Biotechnologies, Inc. Appoints Richard Beckman M.D. as Chief Medical Officer

Adverum Biotechnologies, Inc. Grants Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy

Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022

Independent Director recently sold €95k worth of stock

Chief Business Officer & Acting CFO Christopher DeRespino has left the company

Adverum Biotechnologies, Inc. Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 3000E Growth Index

Independent Chairman recently bought €84k worth of stock

Lexeo Therapeutics, LLC Announces License Agreement with Adverum Biotechnologies, Inc

Adverum Biotechnologies, Inc. Appoints Reed V. Tuckson as an Independent Member to Board of Directors

Adverum Biotechnologies, Inc. Appoints Christopher J. Derespino as Chief Business Officer

Adverum Biotechnologies, Inc. Appoints Leone Patterson as Principal Financial Officer and Principal Accounting Officer

Independent Chairman recently bought €95k worth of stock

Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME

New 90-day low: €8.70

Adverum Biotechnologies, Inc Appoints Dawn Svoronos as Independent Member of Board of Directors

New 90-day high: €11.90

Adverum Biotechnologies, Inc. Announces Positive Interim Data from Cohorts 1-4 from Optic Phase 1 Trial of Advm-022 Intravitreal Gene Therapy for Wet AMD

Revenue misses expectations

New 90-day low: €9.45

Adverum Biotechnologies, Inc. Announces the Appointment of Christopher J. Morrison, as Vice President of Process Science

New 90-day low - €10.20

Adverum Biotechnologies, Inc. has completed a Follow-on Equity Offering in the amount of $188.5 million.

New 90-day low - €12.70

First half earnings released

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Adverum Biotechnologies, Inc.